Is the limit of 60 mg of oral morphine equivalent daily dose (MED) still actual for the access to ROO ′s therapy?
Breakthrough Cancer Pain overlaps to background pain in oncology patient especially in advance stages and requires specific analgesic treatments because it has a different etiology. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 2, 2017 Category: Cancer & Oncology Authors: Luca Miceli, Rym Bednarova, Luigi Vetrugno, Marco Cascella, Arturo Cuomo Source Type: research

Title Page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: research

Information for Readers
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: research

Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: research

Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future
Biliary tract cancers (BTC) are aggressive malignancies associated with resistance to chemotherapy and poor prognostic rates. Therefore, novel treatment approaches are in need. Immunotherapy represents a promising breakthrough that uses a patient ’s immune system to target a tumor. This treatment approach has shown immense progress with positive results for selected cancers such as melanoma and nonsmall cell lung cancer. Initial preclinical data and preliminary clinical studies suggest encouraging mechanistic effects for immunotherapy in B TC offering the hope for an expanding therapeutic role for this disease. (Source: ...
Source: Current Problems in Cancer - October 31, 2017 Category: Cancer & Oncology Authors: Alex B. Blair, Adrian Murphy Source Type: research

Immunotherapy as a Treatment for Biliary Tract Cancers: A Review of Approaches with an Eye to the Future
Biliary tract cancers (BTC) are aggressive malignancies associated with resistance to chemotherapy and poor prognostic rates. Therefore, novel treatment approaches are in need. Immunotherapy represents a promising breakthrough that uses a patient ′s immune system to target a tumor. This treatment approach has shown immense progress with positive results for selected cancers such as melanoma and non small cell lung cancer. Initial preclinical data and preliminary clinical studies suggest encouraging mechanistic effects for immunotherapy in biliary tract cancers offering the hope for an expanding therapeutic role for this ...
Source: Current Problems in Cancer - October 31, 2017 Category: Cancer & Oncology Authors: Alex B. Blair, Adrian Murphy Source Type: research

Anti-PD1/PDL1 induced psoriasis
Immune checkpoint inhibitors are novel agents approved for the treatment of late-stage malignancies. Despite its important clinical benefits, checkpoint inhibition is associated with a unique spectrum of side effects known as immune related adverse events (irAEs). Skin toxicities are the most frequent irAEs during anti-PD1 blockade therapies. Among them, rare cases of psoriasis exacerbation have been reported. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - October 18, 2017 Category: Cancer & Oncology Authors: D. Voudouri, V. Nikolaou, K. Laschos, A. Charpidou, N. Soupos, I. Triantafyllopoulou, I. Panoutsopoulou, G. Aravantinos, K. Syrigos, A. Stratigos Source Type: research

Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes —A systematic review
Familial Colorectal Cancer Type X (FCCTX) is a type of hereditary nonpolyposis colorectal cancer in accordance to Amsterdam criteria-1 for Lynch syndrome, with no related mutation in mismatch repair gene. FCCTX is microsatellite stable and is accounted for 40% of families with Amsterdam criteria-1 with a high age of onset. Thus, the carcinogenesis of FCCTX is different compared to Lynch syndrome. In addition to the microsatellite stability and the presence of less predominant tumors in proximal colon, various clinical features have also been associated with FCCTX in comparison with Lynch syndrome such as no increased risk ...
Source: Current Problems in Cancer - October 17, 2017 Category: Cancer & Oncology Authors: Mahdieh Nejadtaghi, Hamideh Jafari, Effat Farrokhi, Keihan Ghatreh Samani Source Type: research

Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes (a systematic review)
Familial Colorectal Cancer Type X (FCCTX) is a type of hereditary non-polyposis colorectal cancer in accordance to Amsterdam criteria-1(AC1) for Lynch syndrome, with no related mutation in mismatch repair gene (MMR) gene. FCCTX is microsatellite stable and is accounted for 40 % of families with AC1 with a high age of onset. Thus, the carcinogenesis of FCCTX is different compared to lynch syndrome. In addition to the microsatellite stability and the presence of less predominant tumors in proximal colon, various clinical features have also been associated with FCCTX in comparison with lynch syndrome such as no increased risk...
Source: Current Problems in Cancer - October 17, 2017 Category: Cancer & Oncology Authors: Mahdieh Nejadtaghi, Hamideh Jafari, Effat Farrokhi, Keihan Ghatreh Samani Source Type: research

Genomic and epigenetic characterization for the comparison of synchronous bilateral tongue squamous cell carcinomas - a case report
The tongue is the most common and aggressive site for tumors in the oral cavity. These tumors are usually located in the lateral border of the tongue and are often related to the use of tobacco and alcohol. Clinical management of these tumors is predominantly based on anatomic location and TNM classification. The identification of molecular signatures with ability to explain the different outcomes observed in these patients is of paramount importance to guide and help their management. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - October 5, 2017 Category: Cancer & Oncology Authors: Ilda P. Ribeiro, Leonor Barroso, Francisco Marques, Andr é Santos, Francisco Caramelo, Maria J. Julião, Joana B. Melo, Isabel M. Carreira Source Type: research

Synchronous colorectal cancer and multiple myeloma with chest wall involvement: Is this a coincidence?
Multiple primary malignant neoplasms (MPMNs) are rare malignant neoplasms that simultaneously or successively occur in the same patient as two or more primary malignancies. Currently, an increasing number of cases are being reported. In general, MPMNs more commonly occur as two solid tumors or two hematological malignancies. Cases of MPMN that involve a solid tumor and a hematological malignancy are rare. Here, we report a case of synchronous colorectal cancer (CRC) and multiple myeloma (MM) with chest wall involvement. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 25, 2017 Category: Cancer & Oncology Authors: Qiu-Li Li, Jin-An Ma, Hai-Peng Li, Ren-Bing Huang, Chun-Hong Hu, Xian-Ling Liu, Ya-Wen Gao, Gang-Hua Feng, Fang Wu Source Type: research

Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia
The objective of this study was to evaluate whether aprepitant in addition to 5-HT3 receptor antagonist is useful for preventing chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients receiving CHOP therapy, and to evaluate the relationship between in vivo kinetics of plasma substance P and these adverse events. Patients with malignant lymphoma who received CHOP chemotherapy or THP (THP-ADR)-COP therapy were investigated for CINV and anorexia for 5 days after the start of chemotherapy. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 23, 2017 Category: Cancer & Oncology Authors: Mihoko Morita, Shinji Kishi, Miyuki Ookura, Yasufumi Matsuda, Katsunori Tai, Takahiro Yamauchi, Takanori Ueda Source Type: research

Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting and anorexia
The objective of this study was to evaluate whether aprepitant in addition to 5-HT3 receptor antagonist is useful for preventing chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients receiving CHOP therapy, and to evaluate the relationship between in vivo kinetics of plasma substance P and these adverse events. Patients with malignant lymphoma who received CHOP chemotherapy or THP (THP-ADR)-COP therapy were investigated CINV and anorexia for 5 days after start of chemotherapy. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 23, 2017 Category: Cancer & Oncology Authors: Mihoko Morita, Shinji Kishi, Miyuki Ookura, Yasufumi Matsuda, Katsunori Tai, Takahiro Yamauchi, Takanori Ueda Source Type: research

Title Page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 1, 2017 Category: Cancer & Oncology Source Type: research

Information for Readers
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 1, 2017 Category: Cancer & Oncology Source Type: research